Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ingenol mebutate and Dermasil lotion for actinic keratoses
NCT02411851Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ingenol mebutate in actinic keratosis (AK) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Local Skin Reaction at day 57. Started Mar 2015; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02411851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411851.